title: APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.
abstract: To prospectively evaluate the potential influence of resistance to activated protein C (APC-resistance) on the initial inflammatory response, amputation rate and survival during 10 years of follow-up in patients with critical limb ischemia (CLI). Two hundred and fifty-six consecutive CLI patients were analyzed for APC-ratio, the Factor V Leiden mutation and inflammatory mediators and then prospectively followed for 10 years. Inflammatory mediators, amputation rate, morbidity and mortality were compared between patients with and without APC resistance. Of the 256 CLI patients, 35 (14 %) were heterozygotes and 2 (1 %) homozygotes for the Factor V gene mutation, whereas 219 (86 %) patients were non-APC resistant. No significant differences were found between APC resistant and non-APC resistant patients regarding inflammatory mediators. Non-APC resistant patients more often had infrainguinal atherosclerosis (172 [79 %] vs 22 [59 %]; p = 0.017). Amputation rate at 1 year did not differ. Furthermore, there were no significant differences between groups regarding 1-, 3-, 5-, or 10-year survival. APC resistance in patients with CLI was not related to inflammatory activity, and had no impact on limb salvage or rate of amputation or long-term mortality. APC-resistant CLI-patients less frequently had infrainguinal arteriosclerosis, however.
authors.affiliation: Vascular Center, Malmö University Hospital, University of Lund, 20502, Malmö, Sweden, esampram@gmail.com.
authors.forename: Ellis S
authors.initials: ES
authors.lastname: Sampram
authors.forename: Anders
authors.initials: A
authors.lastname: Gottsäter
authors.forename: Bengt
authors.initials: B
authors.lastname: Lindblad
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Svensson
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000671:Amputation, Surgical; D001161:Arteriosclerosis / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000601:surgery; D005121:Extremities / Q000098:blood supply*; D005165:Factor V / Q000235:genetics / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007511:Ischemia / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018836:Inflammation Mediators; C095381:factor V Leiden; D005165:Factor V